uniQure launches $150M public offering to fund gene therapy pipeline
What's the deal? Gene therapy company uniQure (QURE:NASDAQ) has launched a $150 million underwritten public offering of its ordinary shares.
The company is also offering pre-funded warrants to certain investors in place of ordinary shares.
Why now? Biotech firms often tap public markets to raise cash for costly clinical trials and to extend their financial runway.
The post-IPO equity raise gives uniQure fresh capital to advance its gene therapy pipeline.
What could go wrong? Shares of uniQure slipped nearly 3% after the announcement.
Stock dilution from new share issuance can weigh on existing investors, and public offerings often pressure prices in the short term.
The signal: uniQure is a late-stage company focused on delivering single-treatment, potentially curative gene therapies for severe genetic diseases, a development path that demands deep capital reserves. The $150 million raise underscores how even mature gene therapy players must keep returning to equity markets to bankroll the long road from clinical trials to approved cures.
Read more: Seeking Alpha
Image credit: "DNA Double Helix" by National Institutes of Health (NIH) is marked with Public Domain Mark 1.0. To view the terms, visit https://creativecommons.org/publicdomain/mark/1.0/.
